Holyer says that while the committee's proposals could benefit the industry, lobbyists should not expect change to happen overnight.
In this week's podcast, available at www.prweek.com/uk, he comments: 'While the recommendations are worthy it remains to be seen if they can actually be implemented. Just as healthcare spending is rationed, so are the resources NICE has at its disposal.'
Holyer focuses on the report's recommendation that NICE appraises all medicines at launch stage and questions if it is a feasible idea.
'In the next five years we are expecting more than 40 new oncology medicines alone, and it's a question of resources as to whether they can all be appraised. What will count is not what the committee says, but how the Government will respond.'
Take a look at Holyer's Viewpoint at prweek.com/uk.